We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II study of Triapine® in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161).
- Authors
Jennifer Knox; Sebastien Hotte; Christian Kollmannsberger; Eric Winquist; Bryn Fisher; Elizabeth Eisenhauer
- Abstract
Summary Triapine� is a novel small molecule ribonucleotide reductase inhibitor that showed activity in renal cell carcinoma (RCC) cell lines. Evaluating new agents with novel mechanisms remains of interest for patients with incurable RCC. This was a single-arm, multicentre phase II trial where Triapine was given at a schedule of 96 mg/m2 2-h infusion daily � 4 repeated every 2 weeks in patients with recurrent RCC. A median of four cycles of Triapine was administered to 19 eligible patients. One response was seen (7%.) Median time to progression was 3.6 months. Common adverse events (AEs) were grade 1–2, with fatigue in 74%, nausea in 68% and vomiting in 58%. However grade 3/4 neutropenia was seen in 79% and acute reactions of hypoxia, hypotension, methemoglobinemia were seen. Dose reductions/delays due to AEs were common with only 47% of patients receiving > 90% of planned dose intensity. The study closed, at the end of stage 1 as it did not meet the minimal efficacy criteria to proceed. Further evaluation of Triapine at this dose and schedule in patients with advanced kidney cancer is not recommended.
- Subjects
CANADA; CLINICAL trials; CANCER patients; RENAL cell carcinoma
- Publication
Investigational New Drugs, 2007, Vol 25, Issue 5, p471
- ISSN
0167-6997
- Publication type
Article
- DOI
10.1007/s10637-007-9044-9